Cantor Fitzgerald Weighs in on PTCT FY2026 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for shares of PTC Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will post earnings of ($2.69) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $112.00 target price on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to analysts' expectations of $437.16 million. The company's revenue for the quarter was down 9.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.20) earnings per share.

Several other research analysts have also issued reports on PTCT. Citigroup upgraded PTC Therapeutics from a "sell" rating to a "neutral" rating and dropped their target price for the company from $50.00 to $40.00 in a research report on Wednesday, May 7th. Robert W. Baird decreased their price target on PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada upped their price objective on PTC Therapeutics from $57.00 to $58.00 and gave the company an "outperform" rating in a research report on Wednesday, May 7th. Barclays reduced their target price on PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $63.75.

PTC Therapeutics Trading Up 0.5%

NASDAQ:PTCT traded up $0.28 during midday trading on Tuesday, hitting $51.26. 750,739 shares of the company traded hands, compared to its average volume of 868,152. The firm has a market capitalization of $4.06 billion, a P/E ratio of -8.63 and a beta of 0.51. The firm's fifty day moving average is $46.81 and its 200-day moving average is $48.06. PTC Therapeutics has a 12-month low of $28.72 and a 12-month high of $58.38.

Insiders Place Their Bets

In related news, CEO Matthew B. Klein sold 2,804 shares of the company's stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $48.74, for a total transaction of $136,666.96. Following the transaction, the chief executive officer now directly owns 273,234 shares of the company's stock, valued at $13,317,425.16. This represents a 1.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Mark Elliott Boulding sold 883 shares of the firm's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $46.02, for a total value of $40,635.66. Following the completion of the sale, the vice president now directly owns 103,901 shares of the company's stock, valued at approximately $4,781,524.02. This represents a 0.84% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,513 shares of company stock worth $308,498. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On PTC Therapeutics

Hedge funds have recently modified their holdings of the stock. Janney Montgomery Scott LLC boosted its stake in PTC Therapeutics by 8.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 5,965 shares of the biopharmaceutical company's stock worth $269,000 after purchasing an additional 455 shares in the last quarter. Choreo LLC lifted its stake in shares of PTC Therapeutics by 2.0% during the fourth quarter. Choreo LLC now owns 11,961 shares of the biopharmaceutical company's stock worth $541,000 after buying an additional 240 shares during the period. Savant Capital LLC acquired a new stake in shares of PTC Therapeutics during the fourth quarter worth $210,000. Vontobel Holding Ltd. purchased a new stake in shares of PTC Therapeutics during the fourth quarter valued at $521,000. Finally, Rhumbline Advisers increased its position in shares of PTC Therapeutics by 1.5% in the 4th quarter. Rhumbline Advisers now owns 112,401 shares of the biopharmaceutical company's stock valued at $5,074,000 after acquiring an additional 1,630 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.